NEUROENDOCRINE TUMOR G2
Clinical trials for NEUROENDOCRINE TUMOR G2 explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE TUMOR G2 trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE TUMOR G2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in slowing carcinoid tumors
Disease control OngoingThis study tests a drug called pazopanib in 171 people with carcinoid tumors that are getting worse. The goal is to see if pazopanib can slow or stop tumor growth compared to a placebo. Participants take the drug daily and are monitored for how long their disease stays stable.
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Promising drug shows potential to stall neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) better than a placebo. About 298 adults whose cancer worsened after previous treatments will receive either cabozantinib or a dummy pill. The goal is …
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Major trial tests two drug cocktails for Hard-to-Treat carcinoid cancer
Disease control OngoingThis study compares two drug combinations for people with advanced neuroendocrine tumors (carcinoid cancer) that cannot be removed by surgery. Participants receive either octreotide plus interferon or octreotide plus bevacizumab. The goal is to see which combination better delays…
Matched conditions: NEUROENDOCRINE TUMOR G2
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC